Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.95 |
| ▸ | PGR | P06401 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | AR | P10275 | 2/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | APEX1 | P27695 | 1/20 | 0.95 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.95 |
| ▸ | IKBKB | O14920 | 1/20 | 0.95 |
| ▸ | CHUK | O15111 | 1/20 | 0.95 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.95 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.95 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.95 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL516602 | 1.00 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL2637829 | 1.00 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11911310 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13046610 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12738245 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425736-A | Methods for modulating host cell surface interactions with SARS-COV-2 | 基因泰克公司 | 2024-01-19 | — | — | CN | claimed |
| US-20230357418-A1 | RESULTS OF EMPACTA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA | GENENTECH, INC. (US) | 2023-11-09 | — | — | US | claimed |
| EP-4247494-A1 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH SARS-COV-2 | GENENTECH, INC. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116685351-A | Results of EMPACTA: random, double-blind, placebo-controlled, multicenter study for assessing the efficacy and safety of tobrazumab in hospitalized patients with covd-19 pneumonia | 基因泰克公司 | 2023-09-01 | — | — | CN | claimed |
| EP-4213877-A1 | RESULTS OF EMPACTA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA | Genentech, Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| US-20230125415-A1 | BIOMARKERS FOR PREDICTING RESPONSE TO IL-6 ANTAGONIST IN COVID-19 PNEUMONIA | GENENTECH, INC. (US) | 2023-04-27 | — | — | US | claimed |
| CN-115867577-A | Biomarkers for predicting response to IL-6 antagonists in COVID-19 pneumonia | 基因泰克公司 | 2023-03-28 | — | — | CN | claimed |
| EP-4107185-A1 | BIOMARKERS FOR PREDICTING RESPONSE TO IL-6 ANTAGONIST IN COVID-19 PNEUMONIA | Genentech, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2022109441-A1 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH SARS-COV-2 | GENENTECH, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2021194861-A1 | BIOMARKERS FOR PREDICTING RESPONSE TO IL-6 ANTAGONIST IN COVID-19 PNEUMONIA | GENENTECH, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| US-20240228638-A1 | Method for Treating Chronic Obstructive Pulmonary Disease With an ST2 Antagonist | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030926-B2 | Production of heteromultimeric proteins using mammalian cells | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11998562-B2 | Ophthalmological formulations for the prevention of a coronavirus infection | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240158520-A1 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY | HOFFMANN-LA ROCHE INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240158513-A1 | FC Variants and Methods for Their Production | GENENTECH, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2006041680-A2 | METHOD FOR TREATING VASCULITIS | GENENTECH, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060062787-A1 | Method for treating Sjogren's syndrome | GENENTECH, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060024295-A1 | Method for treating lupus | GENENTECH, INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006012508-A2 | METHOD OF TREATING SJÖGREN'S SYNDROME | GENENTECH, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005120437-A2 | METHOD FOR TREATING LUPUS | GENENTECH, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998562-B2 | Ophthalmological formulations for the prevention of a coronavirus infection | SARS1, ACE, ACE2 | NR3C1 4107/4885HIF1A 4701/4885CYP3A4 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.